News
Clinical Data from one research site for GCC19CART, ICT’s lead solid tumor program, for 3rd line plus relapsed/refractory metastatic colorectal cancer (R/R mCRC) shows patients receiving a dose ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback